JAK inhibitor treatment is not associated with stunted growth in children with common inflammatory diseases, according to a ...

Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...

Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) ...

No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MIAMI BEACH, Fla. — Janus kinase inhibitors are an ...

Researchers conducted a multicentric real-world retrospective study of 241 patients across 11 dermatologic centres in the Czech Republic between January 2022 and September 2024. Participants with ...

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to infiltration by ...

Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type ...

Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis. Several patient ...

REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models ...